An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel

Inclusion Criteria:

- Confirmed diagnosis of a solid tumor that is refractory to standard therapies and is
not amenable to treatment with established curative or palliative therapies and for
whom paclitaxel and carboplatin is deemed an acceptable treatment by the investigator

- Males or females ≥18 years of age

- Life expectancy of ≥12 weeks

- Minimum of 1 lesion

- ECOG performance status of 0, 1 or 2

- Adequate bone marrow reserve

- Adequate renal and liver function

Exclusion Criteria:

- Brain metastases that are symptomatic or require ongoing treatment

- Major trauma or surgery within last 2 months, acute infection within 2 weeks (14
days), or radiotherapy, chemotherapy, immunotherapy or hormonal therapy within past 4
weeks

- Persistent grade 2 or greater toxicity related to prior therapy

- Grade 2 or greater peripheral neuropathy

- Recent or current use of Cyp3A4, Cyp2C8 or P-gp inhibitors

- Recent or current use of CYP enzyme inducers